Advertisement

Journal of Molecular Neuroscience

, Volume 69, Issue 4, pp 557–562 | Cite as

Association between Apolipoprotein E Gene Polymorphism and Alzheimer's Disease in an Iranian Population: A Meta-Analysis

  • Morteza Abyadeh
  • Kurosh Djafarian
  • Fatemeh Heydarinejad
  • Shahab Alizadeh
  • Sakineh Shab-BidarEmail author
Article

Abstract

The development of Alzheimer's disease (AD) has been strongly linked to the apolipoprotein E (APOE) polymorphism. A number studies have reported that the APOE ε4 allele is a genetic risk factor for developing AD, whereas the APOE ε2 and APOE ε3 alleles are considered to be neutral or even protective; however, there are conflicting data about these relationships in certain ethnic populations. Several meta-analyses have been performed to reduce the heterogeneity of results from different studies and estimate the real association in specific ethnicities. The aim of this study was to investigate the association between the APOE polymorphism and AD in an Iranian population. Our results showed a higher incidence of AD among individuals carrying the APOE ε4 allele (OR = 4.81, 95% CI: 3.28–7.05), more notably in those with the APOE ε4/e4 genotype (OR = 7.47, 95% CI: 2.35–23.73), while carrying the APOE ε3 allele was demonstrated to have a protective effect (OR = 0.40, 95% CI: 0.30–0.54). The association between the APOE ε2 allele and AD was not statically significant. However, further studies focusing on other parameters such as age, sex and environmental conditions are needed to reveal the true association between the APOE polymorphism and AD.

Keywords

Apolipoprotein E Polymorphism Alzheimer’s disease Meta-analysis 

Notes

References

  1. Agarwal R, Tripathi CB (2014) Association of apolipoprotein E genetic variation in Alzheimer’s disease in Indian population: a meta-analysis. Am J Alzheimers Dis Other Dement 29:575–582CrossRefGoogle Scholar
  2. Alzheimer's Association (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement 9:208–245CrossRefGoogle Scholar
  3. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM (2012) Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. J Biol Chem M111:288746Google Scholar
  4. Bayrami M, Hashemi T, Bonyadi M, Ayromlou H, Nazari M, Tabatabaei S (2011) Apolipoprotein E gene polymorphism in Alzheimer patients in northwest of Iran. Aust J Basic Appl Sci 5:1729–1733Google Scholar
  5. Berlau DJ, Corrada MM, Head E, Kawas CH (2009) APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 72:829–834CrossRefGoogle Scholar
  6. Bezprozvanny I (2009) Amyloid goes global. Sci Signal 2:pe16-pe16CrossRefGoogle Scholar
  7. Castellano JM et al (2011) Human APOE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3:89ra57-89ra57CrossRefGoogle Scholar
  8. Chartier-Hariln M-C et al (1994) Apolipoprotein E, ɛ4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13. 2 chromosomal region. Hum Mol Genet 3:569–574CrossRefGoogle Scholar
  9. Dodart J-C, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM (2005) Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 102:1211–1216CrossRefGoogle Scholar
  10. Farrer LA et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. Jama 278:1349–1356CrossRefGoogle Scholar
  11. Ghayeghran AR, Akbarshahi M, Salehi Z, Davoudi-Kiakalayeh A (2017) Analysis of apolipoprotein E genetic variation in patients with Alzheimer disease referred to Imam Reza Clinic, Rasht, Iran, in 2015. Iran J Neurol 16:173PubMedPubMedCentralGoogle Scholar
  12. Giacobini E, Gold G (2013) Alzheimer disease therapy—moving from amyloid-β to tau. Nat Rev Neurol 9:677CrossRefGoogle Scholar
  13. Gureje O et al (2006) APOE ε4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol 59:182–185CrossRefGoogle Scholar
  14. Harris FM et al (2003) Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci 100:10966–10971CrossRefGoogle Scholar
  15. Holtzman DM et al (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci 97:2892–2897CrossRefGoogle Scholar
  16. Huang Y, Mahley RW (2014) Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis 72:3–12CrossRefGoogle Scholar
  17. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11:193CrossRefGoogle Scholar
  18. Iqbal K et al (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta (BBA)-Mol Basis Dis 1739:198–210CrossRefGoogle Scholar
  19. Jack CR Jr et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:257–262CrossRefGoogle Scholar
  20. Jiang Q et al (2008) APOE promotes the proteolytic degradation of Aβ. Neuron 58:681–693CrossRefGoogle Scholar
  21. Khorshid HK, Gozalpour E, Kamali K, Ohadi M, Karimloo M, Shahhosseiny M (2011) The association between sporadic Alzheimer’s disease and the human ABCA1 and APOE gene polymorphisms in Iranian population. Iran Red Crescent Med J 13:256Google Scholar
  22. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63:287–303CrossRefGoogle Scholar
  23. Lee CD, Tse W, Smith JD, Landreth GE (2012) Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem 287:2032–2044CrossRefGoogle Scholar
  24. Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106CrossRefGoogle Scholar
  25. Liu M, Bian C, Zhang J, Wen F (2014) Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis. Sci Rep 4:4383CrossRefGoogle Scholar
  26. Mak Y et al (1996) Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. Neurology 46:146–149CrossRefGoogle Scholar
  27. Montufar S et al. (2017) Association between the APOE ε4 allele and late-onset Alzheimer’s disease in an Ecuadorian mestizo population. Int J Alzheimer’s Dis 2017Google Scholar
  28. Rajabli F et al (2018) Ancestral origin of APOE ε4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet 14:e1007791CrossRefGoogle Scholar
  29. Raygani AV, Zahrai M, Raygani AV, Doosti M, Javadi E, Rezaei M, Pourmotabbed T (2005) Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Neurosci Lett 375:1–6CrossRefGoogle Scholar
  30. Seet WT, Anne TJAM, Yen TS (2004) Apolipoprotein E genotyping in the Malay, Chinese and Indian ethnic groups in Malaysia—a study on the distribution of the different APOE alleles and genotypes. Clin Chim Acta 340:201–205CrossRefGoogle Scholar
  31. Singh P, Singh M, Mastana S (2006) APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 33:279–308CrossRefGoogle Scholar
  32. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90:1977–1981CrossRefGoogle Scholar
  33. Strittmatter WJ et al (1994) Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 125:163–171CrossRefGoogle Scholar
  34. Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama 283:2008–2012CrossRefGoogle Scholar
  35. Tang M-X et al (2001) Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 56:49–56CrossRefGoogle Scholar
  36. Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, Arrighi HM (2012) Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology 38:1–17CrossRefGoogle Scholar
  37. Wells G, Shea B, O’Connell D, Peterson J, Welch V et al (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Dept of epidemiology and community medicine. University of Ottawa, OttawaGoogle Scholar
  38. Winblad B et al (2016) Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol 15:455–532CrossRefGoogle Scholar
  39. Yu J-T, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer's disease: an update. Annu Rev Neurosci 37:79–100CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Molecular Systems Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and TechnologyACECRTehranIran
  2. 2.Department of Clinical Nutrition, School of Nutritional Sciences and DieteticsTehran University of Medical Sciences (TUMS)TehranIran
  3. 3.Department of Nursing, School of Nursing and MidwiferyShahroud University of Medical SciencesShahroudIran
  4. 4.Department of Community Nutrition, School of Nutritional Sciences and DieteticsTehran University of Medical Sciences (TUMS)TehranIran

Personalised recommendations